17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC

17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) Vol. 51; p. S718
Main Authors: Rini, B, Stenzl, A, Zdrojowy, R, Kogan, M, Shkolnik, M, Oudard, S, Weikert, S, Bracarda, S, Crabb, S, Bedke, J, Ludwig, J, Maurer, D, Mendrzyk, R, Mahr, A, Fritsche, J, Weinschenk, T, Singh, H, Kirner, A, Reinhardt, C, Eisen, T
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2015
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)31939-6